Takeda Oncology Scientific Platforms: Harnessing Innate Immunity for Cancer Treatment | Takeda Oncology
Scientific Platforms
Our Scientific Platforms
Our pipeline focuses on novel strategies that leverage the power of the immune system. Our programs include:
- STING Agonists: STING (selective agonist of STimulator of INterferon Genes) modulation and targeted delivery of STING agonists can influence key interferon signaling pathways and have the potential to drive an immune-mediated, anti-tumor response via multiple innate and adaptive immune mechanisms. In addition, STING agonists have the potential to enhance these anti-tumor effects by relieving immunosuppressive elements in the tumor microenvironment.
- Innate Immune Cell Platforms: Cell therapy approaches in oncology involve treating a patient with immune cells that have been optimized to target tumor cells. We are focused on developing allogeneic cell therapies, which can be derived from external sources and serve as a treatment for many patients. These types of treatments have the potential to be delivered “off-the-shelf” for patients at the time they need therapy and improve upon several aspects of existing cell therapies.
- Tumor-Selective Cell Engagers: Immune cell engagers are conditional bispecific molecules engineered to specifically activate immune system attack at the surface of a tumor. We are developing T cell engagers engineered to take advantage of the tumor’s unique microenvironment to drive T cell activation, triggering cell-mediated killing only at the site of the tumor.
Explore More
Oncology Pipeline
Discovering and developing innovative therapies to deliver potentially transformative treatments.
Partnership Strategy
We believe the best way to achieve our aspiration to cure cancer is by working together.
